

EUFOREA Comment on a Misleading Allergic Rhinitis Report [Letter]

Glenis K Scadding ^{1,*}, Peter K Smith ^{2,*}, Peter W Hellings^{3,4,*}

¹Department of Allergy & Rhinology, Royal National ENT Hospital; Division of Immunity and Infection, University College, London, UK; ²Griffith University, School of Medicine, Southport, Queensland, 4215, Australia; ³Department of Otorhinolaryngology-Head and Neck Surgery, University Hospitals, Leuven, Belgium; ⁴Upper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium

*These authors contributed equally to this work

Correspondence: Glenis K Scadding, Royal National ENT Hospital, 6 Huntley Street, London, W1E 6DG, UK, Tel +442087236045, Email g.scadding@ucl.ac.uk

Dear editor

As members of the EUFOREA Allergic Rhinitis Expert Panel we look for new evidence of effectiveness and acceptability of rhinitis treatments, reflecting EUFOREA's ambition to optimize chronic respiratory disease therapy.¹ Having read "Patient Satisfaction and Sensory Attributes of Nasal Spray Treatments of Olopatadine Hydrochloride/Mometasone Furoate Monohydrate and Azelastine Hydrochloride/Fluticasone Propionate for Allergic Rhinitis in Australia – An Observational Real-World Clinical Study", published in Patient Preference and Adherence 2023:17,141–151² we wish to comment on its concept, conduct and conclusions.

The title "REAL-WORLD" is inappropriate for a skewed, paid, unbalanced patient population, collected via a commercial online portal. The patients studied do not correspond to real world practice in Australia.³

There is marked disparity between patient populations: that of Olopatadine Hydrochloride/Mometasone Furoate Monohydrate (OLO/MOM) was 44% female, versus 76% of the Azelastine Hydrochloride/Fluticasone Propionate (AZE/FLU) population. 77% of OLO/MOM were under 40 years of age versus 63% for AZE/FLU. There was no differentiation of non-allergic rhinitis (NAR) which is a co-factor in approximately 30% of allergic rhinitis (AR) patients, nor for any concomitant nasal structural abnormalities. NAR is associated with nasal hyper-reactivity and is more common in females. AZE/FLU nasal formulation is currently the only treatment with proven efficacy on nasal hyperreactivity (NHR).⁴

Nearly two thirds of those receiving OLO/MOM had a short disease duration of under 12 months vs 50% in the AZE/FLU group. Longer duration of disease involves priming: increased reactivity towards both allergic and non-allergic stimuli following allergen exposure.

There was also a significant difference in treatment background with more OLO-MOM subjects being treatment naive: 51% patients in the OLO/MOM group used less than 1 previous treatment (meaning zero) whereas 75.9% patients in the AZE/FLU group used 1 or more in the last 12 months (Table 1). To be prescribed AZE/FLU patients had to be dissatisfied with their previous treatment and were thus more likely to suffer from severe AR.

Self-determination of treatment, a positive influencer of health outcomes and satisfaction, occurred in 29.2% of the OLO-MOM group but in only 2.1% for AZE/FLU.

Thus there was significant bias in favour of OLO-MOM on several counts. Despite this the outcome which matters to patients, namely efficacy, was superior in the AZE/FLU users ($p < 0.01^{**}$) and the duration of action was also significantly superior when re-scaled for importance. These results were not discussed in the Conclusions.

Another important omission was that of nasal irritation. OLO/MOM formulation has a pH of 3.7 with sucralose as a taste-masking agent. AZE/FLU has a pH of 5.9, without any taste-masking excipients. It is likely that a more acidic pH will cause more nasal irritation.⁵ However, the authors did not discuss the results in this respect.

Table 1 Treatment Background Information of Participants Using Olopatadine Hydrochloride and Mometasone Furoate Monohydrate (OLO/MOM), Participants Using Azelastine Hydrochloride and Fluticasone Propionate (AZE/FLU), and the Full Sample

Treatment Background (N = 426)	OLO/MOM n (%)	AZE/FLU n (%)	Total n (%)
No. of previous treatments in the last 12 months			
Less than 1	50 (51.0%)	79 (24.1%)	129 (30.3%)
Equal to or more than 1	48 (49.0%)	249 (75.9%)	297 (69.7%)
Type of Allergic Rhinitis			
Seasonal Allergic Rhinitis (SAR) only	36 (36.7%)	126 (38.4%)	162 (38.0%)
Perennial Allergic Rhinitis (PAR) only	23 (23.5%)	118 (36.0%)	141 (33.1%)
Both SAR and PAR	38 (38.8%)	79 (24.1%)	117 (27.5%)
Do not know/not sure	1 (1.0%)	5 (1.5%)	6 (1.4%)
Time on current treatment			
Less than 1 year	58 (59.2%)	164 (50.0%)	222 (52.1%)
≥ 1 year ≤ 2 years	24 (24.5%)	103 (31.4%)	127 (29.8%)
> 2 years ≤ 3 years	6 (6.1%)	34 (10.4%)	40 (9.4%)
> 3 years ≤ 4 years	2 (2.0%)	8 (2.4%)	10 (2.3%)
> 4 years ≤ 5 years	2 (2.0%)	8 (2.4%)	10 (2.3%)
More than 5 years	5 (5.1%)	8 (2.4%)	13 (3.1%)
Do not know/not sure	1 (1.0%)	3 (0.9%)	4 (0.9%)
Who recommended current treatment			
Doctor	61 (62.2%)	288 (87.8%)	349 (81.9%)
Pharmacist	29 (2.0%)	27 (8.2%)	56 (13.1%)
Self-managed	6 (29.6%)	7 (2.1%)	13 (3.1%)
Other	2 (6.1%)	6 (1.8%)	8 (1.9%)

Notes: Reproduced from Fifer S, Toh L, Barkate H, et al. Patient Satisfaction and Sensory Attributes of Nasal Spray Treatments of Olopatadine Hydrochloride/Mometasone Furoate Monohydrate and Azelastine Hydrochloride/Fluticasone Propionate for Allergic Rhinitis in Australia – An Observational Real-World Clinical Study. *Patient Prefer Adherence*. 2023;17:141–151.²

Abbreviations: AR, Allergic rhinitis; AZE/FLU, Azelastine Hydrochloride/Fluticasone Propionate; NAR, Non-allergic rhinitis; NHR, Nasal hyperreactivity; OLO/MOM, Olopatadine Hydrochloride/Mometasone Furoate Monohydrate.

Thus the paper which states that patient satisfaction is greater with OLO/MOM than with AZE/FLU is unrepresentative, biased and inaccurate since the most important outcomes: efficacy and duration of action were actually superior in the AZE/FLU treated patients.

Disclosure

GKS: Honoraria for articles, speaker and advisory boards: ALK, Bayer, GlaxoSmithKline, Haleon, Noucor, Sanofi-Regeneron, and Viatri. Chair of BSACI rhinitis guidelines, Scientific Chief Editor, Rhinology Section of Frontiers in Allergy, Board member and AR lead for EUFOREA, and Chair/ member Data Monitoring Committees on SLIT for ALK.

PKS: grants for investigator-initiated research from Hyloris, GSK and Sanofi. He has received honorarium for participating in GA2LEN and Viatri activities and advisory boards for the Nestle Nutrition institute and speaker activities for the latter and GSK. Grants from the Stafford Fox Foundation and the Australian Nation Health and Medical Research Foundation. He has shares in Valneva, a vaccine company. He has patents in detection and modification of TRP receptor dysfunction. He is a member of the EUFOREA rhinitis expert panel.

PWH: Is recipient of consultancy/lecture fees or unrestricted research grants from Sanofi/Regeneron, Novartis, GSK, Medtronic, Stallergenes, Nocour and Viatri.

EUFOREA has received funding from Sanofi/Regeneron, Novartis, Astra-Zeneca, GSK, Stallergenes, ALK, Noucor, Viatri, Johnson and Johnson, EAACI, Covis Pharma Europe BV, Nestlé, Thermo Fisher Scientific and Chiesi for educational and/or research initiatives.

References

1. Hellings PW, Scadding G, Bachert C, et al. EUFOREA treatment algorithm for allergic rhinitis. *Rhinology*. 2020;58(6):618–622. PMID: 329916582. doi:10.4193/Rhin20.376
2. Fifer S, Toh L, Barkate H, et al. Patient satisfaction and sensory attributes of nasal spray treatments of olopatadine hydrochloride/mometasone furoate monohydrate and azelastine hydrochloride/fluticasone propionate for allergic rhinitis in Australia – an observational real-world clinical study. *Patient Prefer Adherence*. 2023;17:141–151. doi:10.2147/PPA.S389875
3. Price DB, Smith PK, Harvey RJ, et al. Real-life treatment of rhinitis in Australia: a historical cohort study of prescription and over-the-counter therapies for patients with and without additional respiratory disease. *Pragmat Obs Res*. 2018;9:43–54. doi:10.2147/POR.S153266
4. Kortekaas Krohn I, Callebaut I, Alpizar YA, et al. MP29-02 reduces nasal hyperreactivity and nasal mediators in patients with house dust mite-allergic rhinitis. *Allergy*. 2018;73:1084–1093. doi:10.1111/all.13349
5. Bustamante-Marin XM, Ostrowski LE. Cilia and Mucociliary Clearance. *Cold Spring Harb Perspect Biol*. 2017;9(4):a028241. PMID: 27864314; PMCID: PMC5378048. doi:10.1101/cshperspect.a028241

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Patient Preference and Adherence 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Patient Preference and Adherence editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Patient Preference and Adherence

Dovepress

Publish your work in this journal

Patient Preference and Adherence is an international, peer-reviewed, open access journal that focusing on the growing importance of patient preference and adherence throughout the therapeutic continuum. Patient satisfaction, acceptability, quality of life, compliance, persistence and their role in developing new therapeutic modalities and compounds to optimize clinical outcomes for existing disease states are major areas of interest for the journal. This journal has been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/patient-preference-and-adherence-journal>